The safety and efficacy of repeated courses of tissue-type plasminogen activator in patients with stuck mitral valves who did not fully respond to the initial thrombolytic course

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 4, 2003, Pages 725-728

  Shapira, Y ^a,b   Vaturi, M ^a,b   Hasdai, D ^a,b   Battler, A ^a,b   Sagie, A ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Prosthetic valve thrombosis; Tissue type plasminogen activator

Indexed keywords

FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; EQUIPMENT; FEMALE; FIBRINOLYTIC THERAPY; HEART VALVE PROSTHESIS; HUMAN; MALE; MIDDLE AGED; MITRAL VALVE; THROMBOSIS; TREATMENT OUTCOME;

ADULT; AGED; EQUIPMENT FAILURE; FEMALE; FIBRINOLYTIC AGENTS; HEART VALVE PROSTHESIS; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 0142228259     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00117.x     Document Type: Article

References (21)

1. Lengyel M, Fuster V, Ketlai M, Roudaut R, Schulte HD, Seward JB, Chesebro JH, Turpie AG. Guidelines for management of left-sided prosthetic valve thrombosis: a role for thrombolytic therapy. Consensus conference on prosthetic valve thrombosis. J Am Coll Cardiol 1997; 30: 1521-6.
2. Bonow RO, Carabello B, de Leon AC, Edmunds LH Jr, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, O'Rourke RA, Rahimtoola SH, Ritchie JL, Cheitlin MD, Eagle KA, Gardner TJ, Garson A Jr, Gibbons RJ, Russell RO, Ryan TJ, Smith SC Jr. ACC/AHA guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). J Am Coll Cardiol 1998; 32: 1486-588.
3. Herring D piper C, Horstkotte D. Management of prosthetic valve thrombosis. Eur Heart J Supplement 2001; Q: Q22-6.
4. Shapira Y, Herz I, Vaturi M, Porter A, Adler Y, Birnbaum Y, Strasberg B, Sclarovsky S, Sagie A. Thrombolysis is an effective and safe therapy in stuck bileaflet mitral valves in the absence of high-risk thrombi. J Am Coll Cardiol 2000; 35: 1874-80.
5. Cambier P, Mombaerts P, De Geest H, Collen D, Van De Werf F. Treatment of prosthetic tricuspid valve thrombosis with recombinant tissue-type plasminogen activator. Eur Heart J 1987; 8: 906-9.
6. Roudaut R, Labbe T, Lorient-Roudaut MF, Gosse P, Baudet E, Fontan F, Besse P, Dallocchio M. Mechanical cardiac valve thrombosis. Is fibrinolysis justified? Initiation 1992; 86 (Suppl. 5): 118-15.
7. Vitale N, Renzulli A, Cerasuolo F, Caruso A, Festa M, de Luca L, Cotrufo M. Prosthetic valve obstruction: thrombolysis versus operation. Ann Thorac Surg 1994; 57: 365-70.
8. Astengo D, Badano L, Bertoli D. Recombinant tissue plasminogen activator for prosthetic mitral-valve thrombosis. N Engl J Med 1995; 333: 259.
9. Renzulli A, Vitale N, Caruso A, Dialetto G, de Luca L, Schinosa T, Cotrufo M. Thrombolysis for prosthetic valve thrombosis: indications and results. J Heart Valve Dis 1997; 6: 212-8.
10. Manteiga R, Carlos Souto J, Altes A, Mateo J, Aris A, Dominguez JM, Borras X, Carreras F, Fontcuberta J. Short-course thrombolysis as the first line of therapy for cardiac valve thrombosis. J Thorac Cardiovasc Surg 1998; 115: 780-4.
11. Munclinger MJ, Patel JJ, Mitha AS. Thrombolysis of thrombosed St. Jude Medical valves: rethrombosis - a sign of tissue ingrowth. J Thorac Cardiovasc Surg 1998; 115: 248-9.
12. Ozkan M, Kaymaz C, Kirma C, Sonmez K, Ozdemir N, Balkanay M, Yakut C, Deligonul U. Intravenous thrombolytic treatment of mechanical prosthetic valve thrombosis: a study using serial transesophageal echocardiography. J Am Coll Cardiol 2000; 35: 1881-9.
13. Vitale N, Renzulli A, de Luca Tupputi Schinosa L, Cotrufo M. As originally published in 1994: Prosthetic valve obstruction: thrombolysis versus operation. Updated in 2000. Ann Thorac Surg 2000; 70: 2182-3.
14. Bonow RO, Carabello B, de Leon AC, Edmunds LH Jr, Fedderly BJ, Freed MD, Gaasch WH, McKay CR, Nishimura RA, O'Gara PT, O'Rourke RA, Rahimtoola SH. Guidelines for the management of patients with valvular heart disease. Circulation 1998; 98: 1949-84.
15. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE Jr, Weaver WD. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996; 28: 1328-428.
16. Task Force on Pulmonary Embolism, European Society of Cardiology. Guidelines on diagnosis and management of acute pulmonary embolism. Eur Heart J 2000; 21: 1301-36.
17. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl. Med 1995; 333: 1581-7.
18. Reddy NK, Padmanabhan T, Singh S, Kumar DN, Raju PR, Satyanarayana PV, Rao DP, Rajagopal P, Raju BS. Thrombolysis in left-sided prosthetic valve occlusion: immediate and follow-up results. Ann Thorac Surg 1994; 58: 462-71.
19. Barbash GI, Hod H, Roth A, Faibel HE, Mandel Y, Miller HI, Rath S, Zahav YH, Rabinowitz B, Seligsohn U, Pelled B, SchlesingerZ, Motro M, LaniadoS, Kaplinsky E. Repeat infusion of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction and early recurrent myocardial ischemia. J Am Coll Cardiol 1990; 16: 779-83.
20. Barbash GI, Birnbaum Y, Bogaerts K, Hudson M, Lesaffre E, Fu Y, Goodman S, Houbracken K, Munsters K, Granger CB, Pieper K, Califf RM, Topol EJ, Van de Werf F. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction, an analysis of outcome and treatment choices in the Global Utilization of Streptokinase and Tissue Plasminogen Activator For Occluded Coronary Arteries (GUSTO I) and Assessment of The Safety of A New Thrombolytic (ASSENT 2) studies. Circulation 2001; 103: 954-60.
21. Kereiakes DJ, Topol EJ, George BS, Abbottsmith CW, Stack RS, Candela RJ, O'Neill WW, Martin LH, Califf RM. Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction. J Am Coll Cardiol 1988; 11: 899-907.